Lipum AB (publ) is a biopharmaceutical firm based in Sweden, focused on... Lipum AB (publ) is a biopharmaceutical firm based in Sweden, focused on pioneering the discovery and development of therapeutic solutions for long-term inflammatory conditions. The company's primary therapeutic asset, SOL-116, is a humanized antibody currently in the late preclinical stage, designed to treat pediatric rheumatism and adult rheumatoid arthritis. To facilitate the advancement of SOL-116 into clinical trials, Lipum has established a collaboration with Pelago Bioscience AB to meticulously monitor drug targets. Founded in 2010, the company's operations are headquartered in Umeå, Sweden.
